drugset
drugset / Trial / NCT00924079

The Development of Oral Nalbuphine Dosage Form

NCT00924079 ↗

Unknown 60 enrolled Tri-Service General Hospital (TSGH)
Non-randomizedCrossoverOpen-label

Summary

The purpose of this study is to investigate possible responses to pharmacokinetic properties for nalbuphine oral formulations in healthy volunteers.

Timeline

Start
2008-09
Primary completion
2009-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Nalbuphine Small molecule 66 mg Oral

Indications

No indication recorded.